低剂量与常规剂量阿司匹林在初次全关节置换术中预防静脉血栓栓塞的对比
该回顾性队列研究纳入2000至2019年间3512例初次全关节置换术(2344例全髋、1168例全膝),比较低剂量(81 mg,27%)与常规剂量(325 mg,73%)阿司匹林每日两次、术后4-6周预防静脉血栓栓塞的效果。结论提示低剂量阿司匹林可能同样有效,但研究把握度不足。
要点
- 低剂量与常规剂量阿司匹林预防VTE的90天发生率无显著差异(0% vs 0.1%)。
- 两组均未发生消化道出血事件,90天死亡率无差异(0.3% vs 0.1%)。
- 研究把握度不足,低剂量阿司匹林的有效性需更大样本验证。
核心结论
- 在3512例初次全关节置换术患者中,每日两次低剂量阿司匹林(81 mg)与常规剂量(325 mg)预防VTE的疗效相当,消化道出血和死亡率无差异,但研究把握度不足。
研究设计与样本
- 回顾性队列研究,纳入2000至2019年间3512例初次全关节置换术(2344例全髋、1168例全膝),低剂量组961例(27%),常规剂量组2551例(73%),术后每日两次阿司匹林用4-6周,平均随访3年。
主要发现
- 两组均无消化道出血事件。
关键数值与推荐
- 低剂量阿司匹林为81 mg,常规剂量为325 mg,均为每日两次、术后使用4-6周。
- 主要终点为90天症状性VTE发生率,次要终点为消化道出血事件和死亡率。
临床怎么用
- 对于初次全关节置换术后VTE药物预防,低剂量阿司匹林(81 mg每日两次)可能可作为常规剂量(325 mg每日两次)的替代选择,但需结合患者个体情况并注意研究把握度不足的局限。
局限性
- 研究为回顾性队列设计,证据等级III级。
- 作者指出研究把握度不足(underpowered)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Consensus on whether low-dose (81 mg) or regular-dose (325 mg) aspirin (ASA) is more effective for venous thromboembolism (VTE) chemoprophylaxis in primary total joint arthroplasties (TJAs) is not reached. The goal of this study is to evaluate the efficacy of low-dose and regular-dose ASA for VTE chemoprophylaxis in primary total hip arthroplasties and total knee arthroplasties. METHODS: We retrospectively identified 3512 primary TJAs (2344 total hip arthroplasties and 1168 total knee arthroplasties) with ASA used as VTE chemoprophylaxis between 2000 and 2019. Patients received ASA twice daily for 4-6 weeks after surgery with 961 (27%) receiving low-dose ASA and 2551 (73%) receiving regular-dose ASA. The primary endpoint was 90-day incidence of symptomatic VTEs. Secondary outcomes were gastrointestinal (GI) bleeding events and mortality. The mean age at index TJA was 66 years, 54% were female, and mean body mass index was 31 kg/m2. The mean Charlson Comorbidity Index was 3.5. Mean follow-up was 3 years. RESULTS: There was no difference in 90-day incidence of symptomatic VTEs between low-dose and regular-dose ASA (0% vs 0.1%, respectively; P = .79). There were no GI bleeding events in either group. There was no difference in 90-day mortality between low-dose and regular-dose ASA (0.3% vs 0.1%, respectively; P = .24). CONCLUSION: In 3512 primary TJA patients treated with ASA, we found a cumulative incidence of VTE <1% at 90 days. Although this study is underpowered, it appears that twice daily low-dose ASA was equally effective to twice daily regular-dose ASA for VTE chemoprophylaxis, with no difference in risk of GI bleeds or mortality. LEVEL OF EVIDENCE: III, retrospective cohort study.
引用
- Uvodich ME, Siljander MP, Taunton MJ, et al. Low-Dose vs Regular-Dose Aspirin for Venous Thromboembolism Prophylaxis in Primary Total Joint Arthroplasty. J Arthroplasty. 2021. PMID: 33640184. doi:10.1016/j.arth.2021.02.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。